What controls PTEN and what it controls (in prostate cancer)

Asian Journal of Andrology

Volumn 14, Issue 1, 2012, Pages 130-131

  Ghosh, Paramita M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ALPHA MANNOSIDASE; ALPHA MANNOSIDASE 2C1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DOWN REGULATION; HUMAN; METASTASIS; NONHUMAN; PATIENT CARE; PHOSPHORYLATION; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84855436923     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.122     Document Type: Review

References (16)

1. Attard G, de Bono JS. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res 2011; 17: 3867-75.
2. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006; 25: 329-37. (Pubitemid 43117618)
3. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007; 67: 6535-8. (Pubitemid 47105495)
4. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-6. (Pubitemid 29418745)
5. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK et al. Determining risk of biochemical recurrence in prostate cancer by immu-nohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860-7. (Pubitemid 47037592)
6. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
7. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-86.
8. He L, Fan C, Kapoor A, Ingram AJ, Rybak AP et al. Alpha-mannosidase 2C1 attenuates PTEN function in prostate cancer cells. Nat Commun 2011; 2: 307.
9. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011; 19: 792-804.
10. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP et al. A pharmacodynamic study of rapamycin in men with intermediate-to high-risk localized prostate cancer. Clin Cancer Res 2010; 16: 3057-66.
11. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007; 5: 433-7. (Pubitemid 351219696)
12. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW et al. Regulation of androgen receptor trans-criptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008; 27: 7106-17.
13. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004; 6: 517-27. (Pubitemid 39469987)
14. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation 2002; 70: 473-85. (Pubitemid 36194313)
15. Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL et al. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int J Oncol 2006; 29: 49-55.
16. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-805. (Pubitemid 33022355)